Generic Rivfloza Availability
Last updated on Mar 13, 2025.
Rivfloza is a brand name of nedosiran, approved by the FDA in the following formulation(s):
RIVFLOZA (nedosiran sodium - solution;injection)
-
Manufacturer: NOVO
Approval date: September 29, 2023
Strength(s): EQ 80MG BASE/0.5ML (EQ 160MG BASE/ML) [RLD], EQ 128MG BASE/0.8ML (EQ 160MG BASE/ML) [RLD], EQ 160MG BASE/ML (EQ 160MG BASE/ML) [RLD]
Has a generic version of Rivfloza been approved?
No. There is currently no therapeutically equivalent version of Rivfloza available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Rivfloza. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Therapeutic inhibition of lactate dehydrogenase and agents therefor
Patent 10,351,854
Issued: July 16, 2019
Inventor(s): Brown Bob D. & Dudek Henryk T. & Lai Cheng
Assignee(s): Dicerna Pharmaceuticals, Inc.This invention relates to compounds, compositions, and methods useful for reducing lactate dehydrogenase target RNA and protein levels via use of dsRNAs, e.g., Dicer substrate siRNA (DsiRNA) agents.
Patent expiration dates:
- October 9, 2035✓✓
- October 9, 2035
-
Therapeutic inhibition of lactate dehydrogenase and agents therefor
Patent 10,738,311
Issued: August 11, 2020
Inventor(s): Brown Bob D. & Dudek Henryk T. & Lai Cheng
Assignee(s): Dicerna Pharmaceuticals, Inc.This invention relates to compounds, compositions, and methods useful for reducing lactact dehydrogenase target RNA and protein levels via use of ds RNAs, e.g., Dicer substrate siRNA (DsiRNA) agents.
Patent expiration dates:
- October 9, 2035✓✓✓
- October 9, 2035
-
Therapeutic inhibition of lactate dehydrogenase and agents therefor
Patent 11,053,502
Issued: July 6, 2021
Inventor(s): Brown Bob D. & Dudek Henryk T. & Lai Cheng
Assignee(s): Dicerna Pharmaceuticals, Inc.This invention relates to compounds, compositions, and methods useful for reducing lactate dehydrogenase target RNA and protein levels via use of dsRNAs, e.g., Dicer substrate siRNA (DsiRNA) agents.
Patent expiration dates:
- October 29, 2035✓✓
- October 29, 2035
-
Methods and compositions for inhibiting expression of LDHA
Patent 11,286,488
Issued: March 29, 2022
Inventor(s): Brown Bob D. & Dudek Henryk T. & Saxena Utsav & Pursell Natalie & Lai Cheng & Wang Weimin & Storr Rachel & Nazef Naim & Kim Boyoung
Assignee(s): Dicerna Pharmaceuticals, Inc.This disclosure relates to oligonucleotides, compositions and methods useful for reducing LDHA expression, particularly in hepatocytes.
Patent expiration dates:
- October 12, 2038✓✓✓
- October 12, 2038
-
Therapeutic inhibition of lactate dehydrogenase and agents therefor
Patent 11,359,203
Issued: June 14, 2022
Inventor(s): Brown Bob D. & Dudek Henryk T. & Lai Cheng
Assignee(s): Dicerna Pharmaceuticals, Inc.This invention relates to compounds, compositions, and methods useful for reducing lactate dehydrogenase target RNA and protein levels via use of ds RNAs, e.g., Dicer substrate siRNA (DsiRNA) agents.
Patent expiration dates:
- October 9, 2035✓✓✓
- October 9, 2035
-
Patent 11,661,604
Patent expiration dates:
- October 12, 2038✓✓✓
- October 12, 2038
Related exclusivities
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
Exclusivity expiration dates:
- September 29, 2028 - NEW CHEMICAL ENTITY
- September 29, 2030 - TO LOWER URINARY OXALATE LEVELS IN CHILDREN 9 YEARS OF AGE AND OLDER AND ADULTS WITH PRIMARY HYPEROXALURIA TYPE 1 (PH1) AND RELATIVELY PRESERVED KIDNEY FUNCTION, E.G., EGFR GREATER THAN OR EQUAL TO 30 ML/MIN/1.73 M^2
More about Rivfloza (nedosiran)
- Compare alternatives
- Pricing & coupons
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: miscellaneous metabolic agents
- En español
Patient resources
Professional resources
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
